Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company based in France. It was founded in 2007 by Prof. Daniel Cohen, a pioneer in genomics, co-founder of Millennium Pharmaceuticals, and his main collaborators. The company develops new therapeutics for severe orphan and common neurological diseases.

The R&D approach pioneered and protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These are then developed at new optimal lower doses and under new formulations.

Pharnext is a privately-held company which has raised a total of €65M since inception.

More : http://pharnext.com/